A Phase I Dose Escalation Trial of WT1-Specific T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 28 Feb 2018
At a glance
- Drugs WT1 protein-specific T-cell therapy Atara/MSKCC (Primary)
- Indications Leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- 23 Feb 2018 Planned End Date changed from 1 Feb 2018 to 1 Feb 2019.
- 23 Feb 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Feb 2019.
- 10 Jun 2017 Biomarkers information updated